Investigational Studies

Oakville, Ontario–(Newsfile Corp. – June 20, 2019) – Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (“Cardiol” or the “Company“), a leader in the research and commercial development of pharmaceutical cannabidiol (CBD) and targeted therapies for heart disease, is pleased to announce that the Company is planning an international clinical trial in acute myocarditis utilizing its […]

LAVAL, Quebec, and ORLEANS, Ontario, Feb. 04, 2019 (GLOBE NEWSWIRE) — Crescita Therapeutics Inc. (“Crescita”) (TSX: CTX), a Canadian commercial dermatology company and Tetra Natural Health (NHP), a subsidiary of Tetra Bio-Pharma, a leader in cannabinoid-derived drug discovery and development, (“Tetra”) (TSX-V: TBP) (OTCQB: TBPMF) today announced an agreement to develop an enhanced version of […]

A CBD-based pharmaceutical drug in development is one more step closer to potential FDA approval. Earlier this week, London-based GW Pharmaceuticals plc, which operates in the United States as Greenwich Biosciences, wrapped up its New Drug Application for Epidiolex, a formulation of the cannabis compound cannabidiol (CBD) for the treatment of seizures associated with two […]

2018 will go down as a re­mark­able year for bio­phar­ma RD, and not just be­cause the in­dus­try post­ed an all-time record high in new drug/bi­o­log­ic ap­provals. Of­fi­cial­ly, there were 59 new mol­e­c­u­lar en­ti­ties — plus a string of bi­o­log­ics — ap­proved last year. Af­ter look­ing over the full list of each new drug ap­proved by CDER last […]

Copyright © 2019 Haymarket Media, Inc. All Rights Reserved This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms Conditions. … read more at: https://www.empr.com/home/news/zulresso-approved-as-first-treatment-for-postpartum-depression/

Copyright © 2019 Haymarket Media, Inc. All Rights Reserved This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms Conditions. … read more at: https://www.empr.com/home/news/zulresso-approved-as-first-treatment-for-postpartum-depression/

GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), the world leader in the development and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich Biosciences, announced today that EPIDIOLEX® (cannabidiol) oral solution CV is now available in the U.S. for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or […]

GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), the world leader in the development and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich Biosciences, announced today that EPIDIOLEX® (cannabidiol) oral solution CV is now available in the U.S. for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or […]

An Indiana University-affiliated venture fund has invested $200,000 in Confluence Pharmaceuticals to continue development of the company’s lead product for the treatment of fragile X syndrome. Along with AOP Orphan Pharmaceuticals, Confluence is developing a novel, clinically discovered adult and pediatric therapy for social and communication impairments related to fragile X and autism spectrum disorders. […]

An Indiana University-affiliated venture fund has invested $200,000 in Confluence Pharmaceuticals to continue development of the company’s lead product for the treatment of fragile X syndrome. Along with AOP Orphan Pharmaceuticals, Confluence is developing a novel, clinically discovered adult and pediatric therapy for social and communication impairments related to fragile X and autism spectrum disorders. […]

Cannabidiol is a non-psychoactive cannabis compound touted for its medicinal promise — but marijuana- and hemp-derived extracts rich in CBD and low in intoxicating THC are facing a future yet to be determined. The Cannabist’s special report “CBD, TBD” explores the issues with CBD — federal-state conflicts, national drug policy, pioneering research efforts and the paths […]